DS-108(DS-108) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

免疫系统疾病皮肤疾病

原研机构

Dignity Sciences Ltd.

在研机构-

非在研机构

Dignity Sciences Ltd.

最高研发阶段终止药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 DS-108 相关的临床结果

登录后查看更多信息

100 项与 DS-108 相关的转化医学

登录后查看更多信息

100 项与 DS-108 相关的专利（医药）

登录后查看更多信息

1

项与 DS-108 相关的文献（医药）

2020-06-01·Drug Development Research3区 · 医学

Discovery of a novel fluorescent chemical probe suitable for evaluation of neuropilin‐1 binding of small molecules

3区 · 医学

Article

作者: Selwood, David L. ; Soudy, Christelle ; Chou, Yi‐Tai ; Dimitriou, Eleni ; Mota, Filipa ; Patsiarika, Anastasia ; Conole, Daniel ; Nwabo, Valery ; Djordjevic, Snezana

AbstractNeuropilin‐1 (NRP1) is emerging as an important molecule in immune signaling where it has been shown to modulate the actions of TGF‐β1 in macrophages and regulatory T cells. The development of cost‐effective and reliable assays for NRP1 binding is therefore important. We synthesized three new NRP1 small molecule fluorophores and examined their performance as fluorescent polarization probes. One molecule DS108 exhibited favorable binding and fluorescent characteristics and allowed us to establish a simple assay suitable for medium to high throughput screening of small molecules.

100 项与 DS-108 相关的药物交易

登录后查看更多信息